Get the Stockscreener App
5.19
1.70%
-0.09
After Hours:
5.19
Foghorn Therapeutics Inc stock is traded at $5.19, with a volume of 82,067.
It is down -1.70% in the last 24 hours and up +6.57% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$5.28
Open:
$5.31
24h Volume:
82,067
Relative Volume:
0.72
Market Cap:
$293.39M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.2179
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
-10.05%
1M Performance:
+6.57%
6M Performance:
+13.32%
1Y Performance:
-41.55%
1-Day Range:
$5.19
$5.44
1-Week Range:
$5.10
$5.85
52-Week Range:
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.19 | 291.13M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Is this a good reentry point in Foghorn Therapeutics Inc.Entry Point & Precise Buy Zone Identification - Newser
Analyzing net buyer seller activity in Foghorn Therapeutics Inc.Rate Hike & Daily Growth Stock Investment Tips - Newser
Earnings visualization tools for Foghorn Therapeutics Inc.2025 Price Targets & Free Long-Term Investment Growth Plans - Newser
Can Foghorn Therapeutics Inc. stock double in the next yearQuarterly Growth Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Technical signs of recovery in Foghorn Therapeutics Inc.Weekly Stock Analysis & Low Risk Growth Stock Ideas - Newser
Foghorn Therapeutics Inc. stock momentum explainedPortfolio Value Report & Growth Focused Entry Reports - Newser
Is Foghorn Therapeutics Inc. forming a bottoming base2025 Geopolitical Influence & Reliable Volume Spike Alerts - Newser
Backtesting results for Foghorn Therapeutics Inc. trading strategiesVolume Spike & Real-Time Price Movement Reports - Newser
Developing predictive dashboards with Foghorn Therapeutics Inc. dataJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - Newser
Is Foghorn Therapeutics Inc. stock reversal real or fakeJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - Newser
What MACD signals say about Foghorn Therapeutics Inc.2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - Newser
Can a trend reversal in Foghorn Therapeutics Inc. lead to recovery2025 Top Gainers & Reliable Price Breakout Signals - Newser
Key metrics from Foghorn Therapeutics Inc.’s quarterly data2025 Major Catalysts & Technical Entry and Exit Tips - Newser
What recovery options are there for Foghorn Therapeutics Inc.2025 Technical Patterns & Free Community Consensus Stock Picks - Newser
Nuveen LLC Makes New $221,000 Investment in Foghorn Therapeutics Inc. $FHTX - MarketBeat
Evaluating Foghorn Therapeutics Inc. with trendline analysisPortfolio Performance Summary & AI Based Buy/Sell Signal Reports - Newser
How to build a custom watchlist for Foghorn Therapeutics Inc.Breakout Watch & High Accuracy Swing Trade Signals - Newser
ranking foghorn therapeutics inc. among high performing stocks via toolsQuarterly Profit Review & AI Powered Market Entry Ideas - Newser
Is now a turning point for Foghorn Therapeutics Inc.Portfolio Performance Report & Technical Pattern Based Signals - Newser
Is it too late to sell Foghorn Therapeutics Inc.Profit Target & Free Growth Oriented Trading Recommendations - Newser
What the charts say about Foghorn Therapeutics Inc. today2025 Geopolitical Influence & Consistent Growth Equity Picks - Newser
What Fibonacci levels say about Foghorn Therapeutics Inc. reboundJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - Newser
Combining machine learning predictions for Foghorn Therapeutics Inc.Bear Alert & Technical Analysis for Trade Confirmation - Newser
Does Foghorn Therapeutics Inc. fit your quant trading modelPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 26% Share Price Surge Not Quite Adding Up - 富途牛牛
What earnings revisions data tells us about Foghorn Therapeutics Inc.July 2025 Outlook & Free Safe Capital Growth Stock Tips - Newser
Using RSI to spot recovery in Foghorn Therapeutics Inc.2025 Big Picture & Fast Gain Swing Alerts - Newser
Statistical indicators supporting Foghorn Therapeutics Inc.’s strengthJuly 2025 Sentiment & Detailed Earnings Play Strategies - Newser
How sentiment analysis helps forecast Foghorn Therapeutics Inc.2025 Volatility Report & Fast Entry and Exit Trade Plans - Newser
When is the best time to exit Foghorn Therapeutics Inc.Fed Meeting & Reliable Price Breakout Signals - Newser
Is Foghorn Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Levels & Real-Time Market Trend Scan - Lancaster City Council
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):